Introduction
Biopsies have been the best tool in the hands of the clinicians for the appropriate management of malignancies including diagnosis, prognosis, and reassessment. They are and have been the gold standard in their diagnosis. Due to certain unavoidable limitations of needle biopsy [ Table 1 ], there is emergence of a new biomarker in oncology called LIQUID BIOPSY: Analysis of circulating tumor cells (CTC) and ctDNA from the peripheral blood. As this technology evolves, it may prove to be a critical component of personalized medicine in this modern era of diagnostics.
The tumor tissue is usually not an issue for early, resectable, and approachable cancers. However, there are some inherent deficiencies with biopsies in inaccessible or advanced malignancies. Modern personalized cancer medicine is largely dependent on finding molecular targets. Intratumoral heterogeneity is an enemy of single biopsies as was scientifically illustrated by Gerlinger et al. [1] when they showed that gene expression signatures differed significantly between biopsies taken from different sites of the primary tumor as well as those from different metastases. Multiple biopsies take intra-and intertumor heterogeneity into consideration but may be difficult, risky, painful, and can potentially cause tumor seeding [2] and fistulas.
Liquid biopsy has a great potential in cancer diagnosis, monitoring, and predicting survival. Nevertheless, false positive results exist. The major challenge with this technology is assay sensitivity and specificity. Several hurdles still exist such as the lack of consensus in technical approaches of choice, preferable sample type, storage conditions, candidate molecules, and suitable detection technique [ Table 2 ]. This mini-review tries to fill the gap between reality and our hope of this "liquid biopsy."
The procedure for collecting the ctDNA/CTC sample is simple. About 1 ml of plasma or serum (3 ml of whole blood) is collected. They have a very short life in blood (few hours) and get cleared by spontaneous disintegration or extravasation into liver, bone marrow, and spleen. [7] Advances in the molecular tests such as targeted sequencing, in-situ hybridization, polymerase chain reaction (PCR), single nucleotide polymorphisms, targeted plasma resequencing (TamSeq), and whole genome/whole exome sequencing (WGS/WES) when applied to ctDNA can provide clinicians with a wealth of useful molecular information.
Clinical Application

Screening and early cancer detection
Current strategies for screening common cancers in high-risk individuals are grossly inadequate, and the role of newer technologies is being sought. The role of CTCs in the early detection of lung cancer in chronic airway disease patients was illustrated by Ilie et al. [8] Another study showed 50% of stage-I lung cancer patients have ctDNA. [9] Similar studies are going on in patients with inflammatory bowel disease. ctDNA can be detected in up to 73% of the patients with localized cancer, often without simultaneous CTC being present. [10] The role of CTCs and ctDNA detection is promising but still in need of significant improvements in specificity and sensitivity. The clinical application is far from reality at present except certain special circumstances.
Prognosis
The presence of CTCs in peripheral blood in patients with breast cancer was associated with poor disease-free survival, breast cancer-specific survival and overall survival with prognosis being worse in those with at least five CTCs in 30 ml of blood with cell search system. [11] The standardization of the cell search system led to the FDA approval of this system for the prognostication in metastatic breast, colorectal, and prostate cancer. [12] CTC enumeration and characterization with certified systems provides reliable information on prognosis and may serve as liquid biopsy to identify therapeutic targets or mechanisms of resistance on metastatic cells such as mutations in KRAS in colon cancer or expression of the androgen receptor variant-7 in prostate cancer patients. PIK3CA mutation detected by digital PCR assay in breast cancer patients is an independent and significant prognostic factor. [13] Detection of new therapeutic targets or reversion of old targets and primary and secondary resistance Detection of resistance mechanisms is the heart of the precision medicine. Analysis of T790M by next generation sequencing of ctDNA in EGFR amplified NSCLC patient's resistance to 1 st line TKI helps us to decide for further treatment in such The importance of repeated Her2/Neu assessment in metastatic breast cancer cannot be over emphasized especially to detect conversion from negative to positive Her2 status. The detection of Her2 to this effect was successfully demonstrated by Gevensleben et al. using digital PCR. [14] Real-time continuous assessment of treatment benefit
Prognostic value of the quantitative estimation of pre-and posttreatment CTCs in metastatic breast cancer was demonstrated in a pooled analysis of individual ctDNA. This also has a role in tracking clonal evolution and drug responses to targeted agents especially by following mutation such as KRAS, NRAS, BRAF, TP53, and PIK3CA.
Taking therapeutic decisions based on liquid biopsy
Clinical trials have an opportunity to prove the clinical benefit of taking therapeutic decisions based on liquid biopsies. Bidard et al. introduced the CTC measurements before and after first cycle of chemotherapy and randomized patients to stay on the same chemotherapy or switching to another therapy. [15] They confirmed the prognostic significance of CTCs in metastatic breast cancer patients. Another study (STIC CTC METABREAST) is ongoing to evaluate the role of CTCs in identifying hormone positive metastatic breast cancer patients who would benefit by early chemotherapy in comparison to hormonal therapy. [16] DETECT III study is exploring the role of anti-Her2 (lapatinib) in multiply treated metastatic TNBC patients with at least one Her 2+ CTC/7.5 ml blood. [17] The use of ctDNA has been successfully shown to predict the clinical benefit of erlotinib in patients with EGFR mutations detected on ctDNA leading to its FDA approval using the companion COBAS EGFR mutation test v2. [18, 19] Difficult to diagnose cancers Inaccessible tumors such as deep pelvic, pancreatic, and bone tumors can be diagnosed with CTCs or ctDNA. There are case reports where synchronous versus metastatic malignancies have been identified by detecting different set of specific mutation. [20] 
